NEC-ONCOIMMUNITY
8.10.2020 09:02:15 CEST | Business Wire | Press release
NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awarded a prestigious grant from the Research Council of Norway (RCN) to develop an artificial intelligence (AI) platform that will enable the rapid design of T-cell diagnostics for emerging or endemic infectious diseases. The project will develop a novel T-cell diagnostic for the current COVID-19 pandemic to complement the current serological tests. This will improve the ability to identify immune responses and acquired immunity, which is desperately needed to deal with the COVID-19 crisis.
Current technologies involve extensive trial and error to define exactly which parts of the pathogen induces robust immunity. These so-called immunodominant epitopes need to be identified for the general population. These demanding, work-intensive and time-consuming steps are necessary to develop tests to monitor the T-cell response to viruses such as SARS-CoV-2 (the infectious virus that causes COVID-19).
Reliable diagnostic tests to identify immune individuals are critical to overcome the ever-looming threat of COVID-19. The AI-based diagnostic to be developed in this project will complement antibody tests and enable individuals who are naturally immune to the virus following infection with SARS-CoV-2 or other seasonal coronaviruses, or who have acquired immunity following vaccination, to be identified.
“Antibody tests are an important aspect of understanding the immune response to the SARS-CoV-2 infection and will remain a mainstay of its diagnosis. However, protective SARS-CoV-2-specific T-cell responses occur in antibody-negative infected individuals who have successfully resolved the infection. In addition, we may already have underlying immunity in the population due to cross reactivity to endemic seasonal human coronaviruses,” said Professor Ludvig A. Munthe Ph.D., Head of Research and Group Leader, Department of Immunology, Oslo University Hospital.
Although the technology to develop antibody diagnostics is readily available, this is not the case for T-cell diagnostics, which currently represents a “blind spot” for the monitoring of immunity to COVID-19 in the world’s population. To address this important gap, NOI and OUH, with the support of RCN, have now committed themselves to develop an AI-designed T-cell diagnostic that monitors the underlying T-cell response to the infection. Developing a reliable T-cell diagnostic comes with specific technological challenges with solutions offered by the NEC Immune Profiler at NOI to cater for the global human population.
“T-cells are known to play a central role for initial and long term immunity against viruses. However, T-cell responses are highly variable between different pathogens and genetic groups in the human population, making the prospect of developing reliable universal T-cell diagnostics for COVID-19 challenging. This challenge has inspired the scientists at NOI to use our AI to seek out the T-cell response to infection as a diagnostic signal. In this project we look forward to adapting the NEC Immune Profiler and other AI technologies at NEC Corporation and leveraging them to develop a COVID-19 T-cell diagnostic for the diverse genetic makeup in the global human population,” said Trevor Clancy Ph.D., Chief Scientific Officer, NEC OncoImmunity AS.
The development of such an AI platform will not only help to contact-trace and control transmission against COVID-19. In fact, the platform developed by NOI and NEC in this project will be to a large degree pathogen/disease agnostic and may be used in future emergency settings to rapidly develop novel diagnostics against new emerging pandemics caused by novel dangerous infectious agents.
“The AI platform will be applied first to the current COVID-19 pandemic. However, we will design this platform to be future-proof and make it applicable to any future emerging infectious agent that could threaten the global population. This will open up new exciting opportunities in the growing infectious disease diagnostics market for our company,” said Richard Stratford Ph.D., Chief Executive Officer, NEC OncoImmunity AS.
It has been over a century since the world has encountered a pandemic like COVID-19. The pandemic has taken over one million lives to date, and the spread of COVID-19 around the globe and the associated mortality has been devastating. The pandemic has sparked fears of a chronic worldwide recession. Shut-downs, social distancing and travel restrictions have reduced the capacity of the global workforce and destroyed many jobs and businesses. The NOI and OUH collaboration marks an important initiative to develop a reliable diagnostic test that can identify immune members of the global population following natural infection with SARS-CoV-2 or other seasonal coronaviruses.
“A reliable T-cell diagnostic to help alleviate the socio-economic and serious health burden caused by COVID-19 will be important for the world community to overcome this present pandemic crisis. We are proud that NEC's AI technology can contribute to the resolution of the COVID-19 threat. As a company that seeks to enhance the well-being of society, NEC will continue to capitalize on research and development that maximizes the strengths of our AI technology to help prevent the spread of COVID-19, and protect the human population against future pandemic threats,” said Akira Kitamura, General Manager of the AI Drug Development Division, NEC Corporation.
About NEC OncoImmunity AS
NEC OncoImmunity AS is a bioinformatics company offering proprietary machine learning-based software called the NEC Immune Profiler, which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. The NEC Immune Profiler can be used to identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit NEC OncoImmunity AS at http://www.oncoimmunity.com/ .
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at http://www.nec.com . For additional information, please also visit NEC Laboratories Europe GmbH at: http://www.neclab.eu
About Oslo University Hospital
Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority and an OECI-accredited Comprehensive Cancer Center (CCC). Each year, more than 1.2 million patient treatments are carried out at the hospital, which is the largest of its kind in Scandinavia. Oslo University Hospital is owned by the South-Eastern Norway Regional Health Authority (HSØ) and delivers specialist healthcare services to patients all over Norway. Oslo University Hospital is Norway’s largest hospital with around 20,000 employees and is responsible for a significant proportion of the medical research and the education of medical personnel in the country. More information about Oslo University Hospital can be found at https://oslo-universitetssykehus.no .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005351/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release
Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release
Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release
Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req
From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release
The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
